rs727504327
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The NM_000116.5(TAFAZZIN):c.347G>A(p.Gly116Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. G116G) has been classified as Likely benign.
Frequency
Consequence
NM_000116.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TAFAZZIN | NM_000116.5 | c.347G>A | p.Gly116Asp | missense_variant | 4/11 | ENST00000601016.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TAFAZZIN | ENST00000601016.6 | c.347G>A | p.Gly116Asp | missense_variant | 4/11 | 1 | NM_000116.5 |
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 24
ClinVar
Submissions by phenotype
3-Methylglutaconic aciduria type 2 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 02, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostics Lab, Nemours Children's Health, Delaware | Aug 24, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Barth syndrome (MIM#302060). (I) 0109 - This gene is associated with X-linked recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to aspartic acid. (I) 0253 - This variant is hemizygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated motif B within the acyltransferase domain (DECIPHER, PMID: 21300850). (I) 0708 - Another missense variant comparable to the one identified in this case has conflicting previous evidence for pathogenicity. This alternative change (p.(Gly116Arg) has been reported in a hemizygous individual with Barth syndrome, but also described as a VUS (PMID: 26845103, LOVD, www.barthsyndrome.org/). (I) 0803 - This variant has limited previous evidence of pathogenicity in unrelated individuals. This variant has been described as likely pathogenic, and observed in at least two individuals with Barth syndrome (LOVD, ClinVar, www.barthsyndrome.org). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Functional studies using a yeast orthologue has demonstrated this variant results in significantly increased monolysocardiolipin (PMID: 21300850). (SP) 1204 - This variant has been shown to be de novo in the proband (parental status not tested but assumed). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Primary dilated cardiomyopathy;C0574083:3-Methylglutaconic aciduria type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 10, 2012 | The Gly116Asp variant in TAZ has been identified in 2 individuals with Barth syn drome (LMM unpublished data, www.barthsyndrome.org) and has not been identified in large and broad European American and African American populations by the NHL BI Exome Sequencing Project (http://evs.gs.washington.edu/EVS). This low frequen cy is consistent with a disease causing role. In addition, functional studies in yeast showed an effect of this variant though this assay may not accurately rep resent biological function in humans (Claypool 2011). Computational analyses (bi ochemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) s uggest that the Gly116Asp variant may impact the protein, though this informatio n is not predictive enough to determine pathogenicity. Finally, the presence of a TAZ variant is consistent with the clinical diagnosis of Barth syndrome in thi s individual's son and most TAZ variants are pathogenic (www.barthsyndrome.org). In summary, this variant is likely to be pathogenic, though additional studies are required to fully establish its clinical significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at